Turin’s industrial roots do not mean every startup should pitch an industrial fund. A therapeutic spinout, an Italian founder building overseas and a B2B software team need different investor paths. Start with the company’s actual state, then combine local relationships with the right specialist capital.
Compare 16 provider families, including 5 documented local or regional routes. Start with the decision framework, use the comparison to screen candidates and save the evidence in the worksheet before you approach anyone.
Choose the right Turin investor path
| Your situation | Research first | Prepare or clarify |
|---|---|---|
| Before team or idea | Investigate Vento’s Reef company-building route separately from its fund. | Decide whether programme participation matches your situation. |
| Italian founder with an early company | Compare Vento and Club degli Investitori with suitable wider firms. | Explain the founder connection, product evidence and global ambition. |
| Therapeutic biology or research-heavy deep tech | Compare Claris and LIFTT, then relevant life-sciences or deep-tech strategies. | Prepare the scientific evidence and development milestone, not a generic sector pitch. |
| B2B software at seed | Compare The Techshop, the relevant Zest route and wider early technology funds. | Show the buyer, adoption and what the round will prove. |
Choose a small first wave you can research properly. Record one reason for fit, one relevant proof point and the next unanswered question for each investor. Move a name out of the active queue when the stage, sector or geographic conditions do not fit.
Compare 16 local and wider investor routes
The connection column distinguishes a documented city or regional route from a wider mandate. It does not imply that every provider has an office here. Initial investment stages and follow-on support are different. This selective list is unranked; each provider family counts once.
| Investor or network | Connection | Entry-stage distinction | Company focus |
|---|---|---|---|
| Vento | Local / regional: Turin base; Italian founders globally | Pre-seed and seed | Across technology sectors |
| Club degli Investitori | Local / regional: Turin-rooted network; Italian founders | Early and later rounds; member-specific | Innovative founder-led companies |
| Claris Ventures | Local / regional: Turin office; science-led companies | Company formation and early clinical development | Differentiated biology and therapeutics |
| LIFTT | Local / regional: Turin-rooted research commercialization | Early development; identify the current vehicle | Deep tech, resources, health, data and industrial resilience |
| Zest | Local / regional: Turin, Rome and Milan locations | Early-stage investment; programme-specific | Technology startup development |
| United Ventures | Wider route: Italian technology; global company ambition | Confirm the relevant fund and entry round | Technology businesses |
| P101 | Wider route: Italian and European technology ecosystem | Fund-specific; confirm commercial readiness | Digital and technology companies |
| Primo Capital | Wider route: Italian ecosystem; strategy-specific | Climate, space, health and digital vehicles differ | Climate, space, health and digital technology |
| Vertis | Wider route: Innovative Italian companies | Startup, scale-up and innovative SME vehicles | Technology and innovative industry |
| CDP Venture Capital | Wider route: Italian innovation; vehicle-specific | Pre-seed onward; direct and indirect routes differ | Technology and strategic industrial sectors |
| 360 Capital | Wider route: Europe; Milan and Paris teams | Pre-seed to Series B | Deep tech, climate and digital-first businesses |
| Panakès Partners | Wider route: Primarily European life-sciences companies | Early-stage; product-specific development | Medical and life-sciences innovation |
| Sofinnova Partners | Wider route: European and international specialist strategies | Company creation through later stages; separate funds | Biopharma, medtech, digital medicine and industrial biotech |
| BlackSheep | Wider route: European AI-native companies | Seed to Series B | Vertical AI and industry workflows |
| Italian Angels for Growth | Wider route: Italian startup ecosystem | Early-company funding; member-specific | Innovative companies across sectors |
| The Techshop | Wider route: Italian B2B digital ecosystem | Seed | B2B digital businesses |
Company building and investment are different decisions
Vento’s fund, Reef and Wave serve different jobs: investment, venture building and ecosystem convening. Zest likewise combines investment with startup development and corporate innovation. Choose the relationship you want before writing a pitch. A team with a product and customers may need a fund conversation; someone before idea and cofounder may benefit more from a structured building programme.
Ask who makes the investment decision, what participation involves and what the company retains control over. Do not count an event, programme and manager as three investor relationships.
Translate industrial expertise into an investable milestone
A prototype that works once, a repeatable manufacturing process and a paying industrial deployment demonstrate different things. A useful Turin pitch states which risk has been reduced and which remains. For an industrial AI product, include the user, deployment constraints and the evidence that the workflow improves. For scientific ventures, separate the biological or technical evidence from the commercial plan.
Use that distinction to decide which specialist should see the company first. The largest investor name is not always the one best equipped for the next experiment.
Italian founder connections are not the same as a Turin office
Vento and the Club describe an Italian-founder connection, while several wider firms focus on Italian or European company development. Those are different geographic filters. Record founder background, incorporation, operating location and customers separately. Do not infer a fund’s domicile rule from the location of one portfolio company.
The national Italy guide remains the broader owner; this guide adds the choice between Turin’s building, scientific and early-company routes.
16 investors and networks to research
1. Vento
Early-stage venture firm. Vento’s fund backs early-stage Italian founders across geographies. That founder connection is different from requiring every company to remain in Turin. Reef is a separate venture-building programme for people before team and idea, while Wave is an event. Count the fund family once and choose the route matching your actual company state.
Approach: Use the Fund information and founder contact. Official Vento information.
2. Club degli Investitori
Angel-investor network. The Club offers a Turin-rooted relationship network for Italian founders building ambitious businesses. Members contribute both capital and operating experience. The published startup application is the starting point; a portfolio example at one stage does not establish an automatic ticket, valuation or investment decision for another company.
Approach: Use Apply with your startup. Official Club degli Investitori information.
3. Claris Ventures
Therapeutics venture investor. Claris combines investment and company creation around early therapeutics. Its Turin address is useful local context, but the decisive screen is the science and route to clinical relevance. A health app or general medical-service business is not the same investment proposition as differentiated therapeutic biology.
Approach: Use Scientists & founders or the company contact. Official Claris Ventures information.
4. LIFTT
Deep-tech investment platform. LIFTT’s current materials distinguish the historic investment company from the newer evergreen structure, for which LIFTT Partners is strategic adviser. Treat this as one provider family and establish the actual decision-making vehicle. Explain the technical risk, commercialization path and why patient development capital is needed.
Approach: Use the published Contact route. Official LIFTT information.
5. Zest
Venture investment and company-development platform. Zest lists a Turin location alongside Rome and Milan and combines investment with startup development and innovation services. Choose the investment route rather than assuming a corporate-service engagement includes capital. Predecessor brands and individual programmes do not become additional independent investors in this list.
Approach: Use the investment scouting and Contact us information. Official Zest information.
6. United Ventures
Technology venture firm. United Ventures backs technology entrepreneurs with a scalable industry-changing product. For a Turin team, the useful first step is to connect its technical advantage with a business model that can travel beyond the local industrial market. Its founder proposal route is distinct from fund-investor enquiries.
Approach: Read the investment FAQ, then submit the founder proposal. Official United Ventures information.
7. P101
Technology investment manager. P101 operates several fund generations rather than one universal startup offer. Identify the appropriate investment team and explain the product, adoption and commercial milestone. Its current investment activity is a research starting point, not evidence that every company resembling a portfolio business qualifies.
Approach: Use the published Contact route. Official P101 information.
8. Primo Capital
Specialist venture platform. Primo separates climate, space, health and digital strategies. A space component and an enterprise software product require different evidence even when both are developed in Turin. Choose the vehicle first and explain the development milestone. Primo Ventures and current Primo Capital branding are one manager here.
Approach: Use the appropriate strategy and Contact us information. Official Primo Capital information.
9. Vertis
Venture and growth investment manager. Vertis invests across startup and later-company development through distinct funds. A Turin industrial company should identify whether its round finances research commercialization, a repeatable product or expansion. Bring a milestone plan and the relevant technical and customer evidence rather than treating all of those stages as seed.
Approach: Use the published firm contact. Official Vertis information.
10. CDP Venture Capital
Direct and indirect venture platform. CDP combines direct-company funds, technology transfer, acceleration and investment into other funds. Only a matching founder-facing route belongs in your active queue. A public programme headline is not an application to all CDP capital, and an indirect fund allocation is not a direct startup cheque.
Approach: Identify a direct company-facing fund or active programme. Official CDP Venture Capital information.
11. 360 Capital
European technology venture firm. 360 publishes an early-stage European remit from pre-seed through Series B. That makes the actual stage and technology thesis more useful than office proximity. Explain the product advantage and the next proof point, then use the dedicated pitch route instead of an unrelated portfolio-company contact.
Approach: Use Pitch now. Official 360 Capital information.
12. Panakès Partners
Life-sciences venture firm. Panakès is a specialist medical and life-sciences route. A team should explain the unmet need, scientific or product evidence and development plan. Do not substitute a general healthcare-market slide for a clear account of what the product must demonstrate next.
Approach: Use Submit a project. Official Panakès Partners information.
13. Sofinnova Partners
Life-sciences investment firm. Sofinnova spans several stages and scientific disciplines through different strategies. A therapeutic programme and a sustainable industrial process should not be pitched as interchangeable life-sciences opportunities. Identify the appropriate team and the experiment or commercial milestone that reduces the most important risk.
Approach: Use the project or Contact Us route for the relevant strategy. Official Sofinnova Partners information.
14. BlackSheep
Vertical-AI venture firm. BlackSheep’s current thesis is vertical AI, with a new-fund announcement dated November 12, 2026. A Turin company should identify the industry buyer and explain how its AI changes a consequential workflow. Generic AI branding is less useful than evidence of a durable product advantage.
Approach: Use Submit a Pitch in Contacts. Official BlackSheep information.
15. Italian Angels for Growth
Angel-investor community. IAG combines members’ capital, operating experience and professional relationships. It is a community of investors rather than one automatic pooled-fund decision. Prepare a concise company case and be clear about the expertise needed alongside capital, then follow the startup selection process.
Approach: Use the Startup route. Official Italian Angels for Growth information.
16. The Techshop
Seed venture firm. The Techshop explicitly emphasizes seed-stage B2B digital companies. A Turin software company should make the business buyer, product roadmap and evidence of demand easy to understand. Its general site contact asks founders to use the dedicated investment route, so keep the proposal out of unrelated enquiries.
Approach: Use the dedicated investment-proposal page. Official The Techshop information.
A Turin industrial-AI team builds its first wave
Fictional worked example. A Turin company has a machine-inspection prototype and one unpaid factory pilot. Its Italian founders want a seed round to make the product repeatable. The pilot has not yet established recurring revenue.
| Candidate | Next action | Why it changes the decision |
|---|---|---|
| Vento | Prepare the product insight and Italian-founder connection. | An early founder mandate differs from a mature revenue requirement. |
| LIFTT | Explain technical risk and the commercialization milestone. | Research-to-market capital needs an evidence-led development plan. |
| The Techshop | Clarify whether the product is a repeatable B2B digital business. | A custom engineering service is a different proposition. |
| Claris | Exclude from this immediate queue. | An industrial inspection product is not therapeutics. |
The aim is a more coherent queue, not the largest possible one. Connect the proposed round with an achievable milestone using the round-size planning worksheet.
Build your Turin investor-fit worksheet
Use one card for each provider and strategy. It works in a document, spreadsheet or your Finta research notes. Keep facts, expectations and questions in separate fields.
INVESTOR FIT CARD: TURIN
Company, current evidence and next funding milestone: [authorised facts]
Founder/company geography: Italian founder / Turin operations / other
Path: fund / venture building / specialist science / growth
Technical evidence: prototype / repeatable system / customer deployment
Commercial evidence: unpaid pilot / paid trial / recurring use
Investor and specific vehicle: [current name; avoid rebrand duplicates]
Official stage, sector and geographic criteria: [URL; date]
Fit evidence: [what matches; not just a portfolio resemblance]
Mismatch or open question: [the unresolved issue]
Approach route: [founder form / network selection / general enquiry]
Relationship context: [known person; permission to ask; or public route]
Lead/co-investment status: [unknown / conditional / confirmed]
Owner, next action and follow-up date: [person; action; date]Bring the shortlist into Finta to keep investor research, relationship context and follow-up connected. Aurora can help organise the context and prepare a next move for your review. You stay in control of the approach and information shared.
Review your shortlist with Aurora, Claude or Codex
Paste the prompt with the public sources and company information you are authorised to use. Check its output against the sources before acting.
Help me research investor fit for a Turin startup.
Company, location, current evidence and funding milestone: [authorised facts]
Candidates and official sources: [names, URLs and research dates]
Separate local offices, regional operating requirements and wider investment eligibility.
Check the specific vehicle, initial stage, sector, company conditions and public approach route.
Keep university programmes, angel networks, direct equity, grants and commercial partnerships distinct.
Count each manager or rebrand once. Do not assume a portfolio investment proves current eligibility.
Return a table: source, fit evidence, mismatch, unknown, next question and owner.
Flag missing or contradictory evidence instead of filling gaps.
Suggest a short first research wave and explain exclusions.
Do not contact anyone, submit forms or share confidential information.Keep the wider fundraising process connected with the pre-seed guide, Seed Fundraising Comprehensive Guide and investor-prospecting workflow. For national coverage, see the Italy investor guide.
Methodology and research date
By Finta Editorial Team. Official investor, public-institution and company materials reviewed November 13, 2026, with source-dated prior research used for discovery. 16 provider families are included: 5 documented local or regional routes and 11 wider mandates. Angel networks are identified as networks, not pooled funds. Company-building and strategic investment routes are labelled separately.
Startup Genome’s 2026 Emerging Ecosystems ranking informed city selection; it is not an investor ranking or endorsement. Current official materials support the profiles. A published thesis is not a promise of available capital, current intake or an investment outcome. Confirm open questions directly.
Not counted or kept separate:
- Reef, Wave, predecessor Zest brands and individual CDP programmes are not counted as extra independent managers.
- Neva is kept outside this edition while its current vehicle-specific entry criteria are being clarified.
General information, not personalised financial, legal or tax advice. Programme and company criteria are research filters, not an eligibility ruling. The cover is an editorial ecosystem illustration, not a map of investor offices or actual financing flows.